MedTrace Logo

AI-based Progression and Medication Response Prediction Study in Parkinson's Disease

NCT07189468 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-09-24

No results posted yet for this study

Summary

The study aims to provide initial PoC validation data of two AI models to predict disease progression and treatment side effects in PD patients using as input patients' demographic, clinical and genetic information, as well as digital biomarker measurements in daily living collected via a smartwatch and a mobile application.

Conditions

  • PARKINSON DISEASE (Disorder)

Interventions

DEVICE

Smartwatch and mobile application

Wearing a smartwatch and using a mobile application for one year

Sponsors & Collaborators

  • Aristotle Univ. of Thessaloniki (Greece)

    collaborator UNKNOWN

  • University Hospital, Toulouse

    lead OTHER

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-06
Primary Completion
2027-04-01
Completion
2027-04-01

Countries

  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07189468 on ClinicalTrials.gov